Cynthia Seidel-Dugan - 06 Jan 2022 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Role
Chief Scientific Officer
Signature
/s/ Reid Leonard, Attorney-in-fact
Issuer symbol
HOWL
Transactions as of
06 Jan 2022
Net transactions value
+$111,838
Form type
4
Filing time
14 Jan 2022, 16:58:50 UTC
Next filing
09 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HOWL Common Stock Options Exercise $37,750 +24,199 +19% $1.56 149,356 12 Jan 2022 Direct
transaction HOWL Common Stock Options Exercise $74,088 +15,532 +10% $4.77 164,888 12 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOWL Stock Option (right to buy) Award $0 +79,516 $0.000000 79,516 06 Jan 2022 Common Stock 79,516 $11.55 Direct F1
transaction HOWL Stock Option (right to buy) Options Exercise $0 -24,199 -40% $0.000000 36,937 12 Jan 2022 Common Stock 24,199 $1.56 Direct F2
transaction HOWL Stock Option (right to buy) Options Exercise $0 -15,532 -16% $0.000000 83,631 12 Jan 2022 Common Stock 15,532 $4.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026.
F2 The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024.
F3 The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.